EMA Revises Risk Management Guidelines
The agency has revised its good pharmacovigilance practices guide on risk management systems.
The European Medicines Agency (EMA) has revised module V of the good pharmacovigilance practices (GVP) on risk management systems based on insights from EMA’s Pharmacovigilance Risk Assessment Committee (PRAC). Public consultation on the revised guidelines is open until May 31, 2016.
The revision clarifies the requirements a risk management plan should focus on “to ensure that a risk-proportionate planning of activities directs resources to areas where the need for additional information and risk minimization is greatest. EMA states that the GVP module V should be read in conjunction with GVP module XVI, which focuses on tools for risk minimization.
EMA is also looking to amend the risk management plan template used by drug developers in order to focus the risk management system and simplify transfer of information to regulators. Public consultation on the revised template is also open until May 31, 2016.
Source: EMA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
